Scott W. Morrison - 12 Jun 2025 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Reporting relationship: Director
Issuer ticker: CRVS
Reported as of: 12 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2025, 16:27:07 UTC
Prior SEC filing: 16 May 2025
Next SEC filing: 23 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Leiv Lea, as Attorney-in-Fact for Scott W. Morrison

Key filing fact

Scott W. Morrison filed Form 4 for Corvus Pharmaceuticals, Inc. (CRVS) on 16 Jun 2025.

Key facts

This page summarizes Scott W. Morrison's Form 4 filing for Corvus Pharmaceuticals, Inc. (CRVS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2025, 16:27.

Change

Previous filing in this sequence was filed on 16 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001662426 Primary reporting owner

Morrison Scott W

Relationship: Director
Address: C/O CORVUS PHARMACEUTICALS, INC., 901 GATEWAY BOULEVARD, THIRD FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Leiv Lea, as Attorney-in-Fact for Scott W. Morrison
Signature date: 16 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRVS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 12 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $4.24
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.